| |
Baseline (n = 36)
|
Week 12 (n = 36)
|
Week 24 (n = 36)
|
1 year (n = 36)
|
|---|
|
Age, median (range) years
|
54 (33-79)
| | | |
|
% female
|
77%
| | | |
|
Disease duration, median (range) years
|
9 (2-33)
| | | |
|
RF positive
|
36
|
|
ACPA positive
|
28
|
|
RF/ACPA positive
|
28
| |
| |
mean ± SEM
| | | |
|
DAS28 score
|
5.2 ± 0.3
|
3.3 ± 0.3ψ
|
2.7 ± 0.2ψ
|
1.9 ± 0.2ψ
|
|
CRP, mg/dl
|
0.9 ± 0.1
|
0.14 ± 0.06ψ
|
0.09 ± 0.03ψ
|
0.06 ± 0.02ψ
|
|
ESR, mm/hour
|
32.1 ± 3.4
|
9.8 ± 1.6ψ
|
7.2 ± 0.9ψ
|
5.6 ± 0.8ψ
|
|
Patient’s VAS
|
58.3 ± 4.4
|
48.6 ± 4.8ψ
|
34.8 ± 5.4ψ
|
21.5 ± 4.8ψ
|
|
IgA-RF U/ml
|
122.3 ± 33.3
|
99.9 ± 26.3ψ
|
63.3 ± 19.8ψ
|
-
|
|
IgA total U/ml
|
265.4 ± 20.8
|
237.2 ± 19.5ψ
|
203.1 ± 18.9ψ
|
-
|
- The primary end point of the study was a reduction in the disease activity score in 28 joints (DAS28) at week 12. Except where indicated otherwise, values are the mean ± standard error of the mean (SEM). ψ
P <0.05 versus baseline and Mann-Whitney t test was used for statistics. RF, rheumatoid factor; ACPA, anti-citrullinated protein antibodies; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; VAS, visual analog scale (100 mm); IgA, immunoglobulin A.
